

deucravacitinib film-coated tablets (Sotyktu®)

SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2581	Indication under review: for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. SMC restriction: patients who have failed to respond to standard systemic therapies (including ciclosporin, methotrexate and phototherapy), are intolerant to, or have a contra-indication to these treatments.	Available in line with local or regional guidance	20/12/2023	21/02/2024
Other Decision Specified :				
Web Link : https://www.scottishmedicines.org.uk/media/7992/deucravacitinib-sotyktu-final-nov-2023-amended-011223-for-website.pdf				

cemiplimab concentrate for solution for infusion (Libtayo®)

SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2584	Indication under review: as monotherapy for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) who are not candidates for curative surgery or curative radiation.	Available in line with local or regional guidance	20/12/2023	21/02/2024
Other Decision Specified :				
Web Link : https://www.scottishmedicines.org.uk/media/7989/cemiplimab-libtayo-final-nov-2023-for-website.pdf				

cipaglucoisidase alfa powder for concentrate for solution for infusion (Pombiliti®)

SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2606	Indication under review: as a long-term enzyme replacement therapy used in combination with the enzyme stabiliser miglustat for the treatment of adults with late-onset Pompe disease (acid α -glucosidase [GAA] deficiency)	Available in line with national guidance	20/12/2023	15/11/2023

Other Decision Specified :

Web Link : <https://www.scottishmedicines.org.uk/media/7990/cipaglucoisidase-alfa-pombiliti-abb-final-nov-2023-for-website.pdf>

trastuzumab deruxtecan powder for concentrate for solution for infusion (Enhertu®)

SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2608	Indication under review: as monotherapy for the treatment of adult patients with unresectable or metastatic HER2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy. In an open-label, randomised, phase III study, trastuzumab deruxtecan significantly improved progression-free survival compared with single-agent chemotherapy in patients with HER2-low, hormone receptor-positive, unresectable or metastatic breast cancer who had received one or two lines of prior chemotherapy in the metastatic setting	Available in line with local or regional guidance	20/12/2023	21/02/2024
Other Decision Specified :				
Web Link : https://www.scottishmedicines.org.uk/media/7996/trastuzumab-deruxtecan-enhertu-final-nov-2023-amended-011223-for-website.pdf				

bimekizumab solution for injection in pre-filled syringe and pre-filled pen (Bimzelx®)

SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2616	For the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs (NSAIDs) and adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	20/12/2023	21/02/2024

Other Decision Specified :

Web Link : <https://www.scottishmedicines.org.uk/medicines-advice/bimekizumab-bimzelx-axspa-abb-smc2616/>

nivolumab concentrate for solution for infusion (Opdivo®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2619	<p>Indication under review: in combination with platinum-based chemotherapy for the neoadjuvant treatment of resectable (tumours ≥ 4 cm or node positive) non-small cell lung cancer in adults.</p> <p>In an open-label, randomised, phase III study, the addition of nivolumab to platinum-based chemotherapy as neoadjuvant treatment was associated with significant benefits in event-free survival and pathological complete response in patients with stage IB to IIIA resectable non-small cell lung cancer</p>	Available in line with local or regional guidance	20/12/2023	21/02/2024
Other Decision Specified :				
Web Link : https://www.scottishmedicines.org.uk/media/7994/nivolumab-opdivo-final-nov-2023-amended-011223-for-website.pdf				

degarelix injection (Firmagon®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2625	<p>Indication under review:</p> <ul style="list-style-type: none"> • for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. • as neoadjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer. 	Available in line with local or regional guidance	20/12/2023	21/02/2024
Other Decision Specified :				
Web Link : https://www.scottishmedicines.org.uk/media/7991/degarelix-firmagon-abb-final-nov-2023-for-website.pdf				
amivantamab concentrate for solution for infusion (Rybrevant®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2638	<p>Indication under review: as monotherapy for treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) Exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy.</p>	Not routinely available as not recommended for use in NHS Scotland	20/12/2023	20/12/2023
Other Decision Specified :				
Web Link : https://www.scottishmedicines.org.uk/media/7987/amivantamab-rybrevant-non-sub-final-nov-2023-for-website.pdf				

lumasiran solution for injection (Oxlumo®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2639	Indication under review: Treatment of primary hyperoxaluria type 1 (PH1) in all age groups.	Not routinely available as not recommended for use in NHS Scotland	20/12/2023	20/12/2023
Other Decision Specified :				
Web Link : https://www.scottishmedicines.org.uk/media/7993/lumasiran-oxlumo-non-sub-final-nov-2023-for-website.pdf				
osilodrostat film-coated tablets (Isturisa®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2640	Indication under review: treatment of endogenous Cushing's syndrome in adults	Not routinely available as not recommended for use in NHS Scotland	20/12/2023	20/12/2023
Other Decision Specified :				
Web Link : https://www.scottishmedicines.org.uk/media/7995/osilodrostat-isturisa-non-sub-final-nov-2023-for-website.pdf				